Patient-Reported Outcomes Improve With Current RA Tx

Patient-Reported Outcomes Improve With Current RA Tx

Patients with rheumatoid arthritis (RA) with inadequate response to methotrexate report clinically meaningful improvements across a broad range of outcomes after adding either tofacitinib (Xeljanz) or adalimumab (Humira), a new analysis shows. After 3

(Visited 1 times, 1 visits today)
2
Like
Save

Comments

Comments are disabled for this post.